In the SURPASS-1 trial 705 individuals with short duration T2DM (mean 4.7 years, mean HbA1c ~ 8.0%) were randomized to placebo or escalating doses of tirzepatide a novel “twincretin” with glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist activity, recently approved by the FDA for the treatment of type 2 diabetes44. The gene discussed is GCG; the disease is type 2 diabetes mellitus.